ARA-290
An erythropoietin-derived peptide fragment studied for tissue-protective and neuropathy-related applications without the red-blood-cell effects of full EPO.
Also referenced as: Cibinetide
This compound has a genuine development or study trail, but it is not an approved routine drug.
This profile is grouped by its dominant research and market lane, not by vendor shelf placement.
Cibinetide
No FDA label signal · 4 trials · 76 PubMed results
What ARA-290 is
ARA-290 is a small peptide derived from the tissue-protective region of erythropoietin. It is usually discussed as a way to explore anti-inflammatory and repair-oriented signaling without using full erythropoietin as a drug.
Why it matters
It shows up in the peptide market because it sits at the intersection of pain, small-fiber neuropathy, and tissue recovery. That gives it a very different profile from the more common tendon-and-muscle repair peptides.
Regulatory context
ARA-290 is not an FDA-approved therapy in the United States. It is best understood as an investigational compound with a more clinical backstory than many research-market entries.
Practical reading note
When this compound appears in vendor catalogs, the important distinction is that investigational interest does not equal routine clinical availability.